Advances in the Research and Application of CAR-T Cell Therapy in Tumor Therapy

Cancer is a frightening thing in people's eyes. With the change of people's living habits, eating habits, living environment, etc., more and more various diseases haunt us. It is even said that the improvement of the level of technology has enabled us to discover diseases that had not been discovered before. Tumor, there are good and bad points, but also easy to absorb human nutrition, damage people's lives. Therefore, cancer therapy research is related to people's hope of anti-cancer treatment. With the continuous improvement of gene editing technology, the research of CAR-T cell therapy (CT) has made remarkable progress. CAR-T CT, or chimeric antigen receptor T CT, is a revolutionary approach to cancer treatment. It is based on genetic engineering technology, by modifying the patient's own T cells, so that they have the ability to specifically recognize and attack tumor cells. Although chemotherapy and radiotherapy can inhibit the growth of tumors to a certain extent, they are often accompanied by serious side effects such as nausea, vomiting, fatigue, and greater damage to normal cells. In contrast, CAR-T CT has higher targeting and lower side effects. It can achieve the purpose of treating tumors without damaging normal cells. This paper analyzes the role of CAR-T CT in hematologic tumors and solid tumors, so as to provide further evidence for tumor treatment. This paper investigates and analyzes the basic changes of myeloma patients before and after receiving CT and the status of carcinoembryonic antigen, cytokeratin 19 fragment and neuron-specific enolase in lung cancer patients. The blood pressure values of myeloma patients varied from 110 to 130 during the test. Lung cancer patients had smaller fluctuations in neuron-specific enolase, and there was some independence between this tumor marker and the effect of CAR-T CT. The effect of CT on the expansion of B-cell mature antigen in blood is weaker than that in bone marrow.